Objective: To evaluate the risk factors, physician's compliance, and implementation of the American College of Chest Physicians (ACCP) guidelines for venous thromboembolism (VTE) prophylaxis at our hospital. Methods: A retrospective cohort study was conducted in King Fahad Hospital, Madinah, Saudi Arabia, from July 2015 to September 2015. We used the ACCP 2012 guidelines to assess the VTE risk and to determine whether patients had received the recommended prophylaxis. All hospital inpatients aged 14 years or older were assessed for risk of VTE by reviewing the hospital chart. The primary endpoint was the rate of appropriate thromboprophylaxis. Results: A total of 414 patients were studied. Their mean age was 47.74 ± 20.4 years, and 208 (50....
Abstract Background Venous thromboembolism (VTE) is a silent and potentially lethal disease that a...
Introduction: venous thromboembolism is a complication among admitted medical and surgical patients....
BACKGROUND: Chemoprophylaxis is recommended for medical patients at moderate to high risk of venous ...
Abstract Background Venous thromboembolism (VTE) is a leading cause of hospital-related deaths world...
BACKGROUND: Information about the variation in the risk for venous thromboembolism (VTE) and in prop...
Aim: The aim is to assess risk and evaluate the usage of pharmacological thromboprophylaxis adhering...
BACKGROUND: There are not information about the risk of venous thromboembolism (VTE) and its prophyl...
387-394Information about the variation in the risk for venous thromboembolism (VTE) and in prophylax...
Q1Q1736-748Limited data are available regarding the risk for venous thromboembolism (VTE) and VTE p...
Limited data are available regarding the risk for venous thromboembolism (VTE) and VTE prophylaxis u...
OBJECTIVE: To evaluate venous thromboembolism (VTE) risk in patients who underwent a major operation...
Limited data are available regarding the risk for venous thromboembolism (VIE) and VIE prophylaxis u...
Deep vein thrombosis and pulmonary embolism are significant reasons of chronic illness & death in pe...
Background: Venous thromboembolism (VTE) is a serious and underestimated potentially fatal disease w...
Venous thromboembolism (VTE) acquired during hospitalization is common, yet preventable by the prope...
Abstract Background Venous thromboembolism (VTE) is a silent and potentially lethal disease that a...
Introduction: venous thromboembolism is a complication among admitted medical and surgical patients....
BACKGROUND: Chemoprophylaxis is recommended for medical patients at moderate to high risk of venous ...
Abstract Background Venous thromboembolism (VTE) is a leading cause of hospital-related deaths world...
BACKGROUND: Information about the variation in the risk for venous thromboembolism (VTE) and in prop...
Aim: The aim is to assess risk and evaluate the usage of pharmacological thromboprophylaxis adhering...
BACKGROUND: There are not information about the risk of venous thromboembolism (VTE) and its prophyl...
387-394Information about the variation in the risk for venous thromboembolism (VTE) and in prophylax...
Q1Q1736-748Limited data are available regarding the risk for venous thromboembolism (VTE) and VTE p...
Limited data are available regarding the risk for venous thromboembolism (VTE) and VTE prophylaxis u...
OBJECTIVE: To evaluate venous thromboembolism (VTE) risk in patients who underwent a major operation...
Limited data are available regarding the risk for venous thromboembolism (VIE) and VIE prophylaxis u...
Deep vein thrombosis and pulmonary embolism are significant reasons of chronic illness & death in pe...
Background: Venous thromboembolism (VTE) is a serious and underestimated potentially fatal disease w...
Venous thromboembolism (VTE) acquired during hospitalization is common, yet preventable by the prope...
Abstract Background Venous thromboembolism (VTE) is a silent and potentially lethal disease that a...
Introduction: venous thromboembolism is a complication among admitted medical and surgical patients....
BACKGROUND: Chemoprophylaxis is recommended for medical patients at moderate to high risk of venous ...